<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03717454</url>
  </required_header>
  <id_info>
    <org_study_id>DD2RP-2018</org_study_id>
    <nct_id>NCT03717454</nct_id>
  </id_info>
  <brief_title>Dopamine D2 Receptors(D2R) Imaging in Prolactinomas</brief_title>
  <official_title>The Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of of Prolactinomas.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhebao Wu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of China Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the in vivo expression of dopamine D2 receptors in prolactinoma and the predictive
      role of dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The dopamine agonist(DA),such as cabergoline(CAB) and bromocriptine(BC), has been used widely
      in the treatment of prolactinomas, but its clinical use is hampered by intolerance and/or
      resistant in some patients. It had been showed that DA inhibit prolactin secretion by binding
      to and activating dopamine D2 receptors.PET-MR combined MR images with PET function images is
      substantial to evaluate the expression of dopamine D2 receptors.The aim is to study the in
      vivo expression of dopamine D2 receptors in prolactinoma and the predictive role of dopamine
      D2 receptors PET-MR imaging in the therapeutic effect of DA.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline on PRL level</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Record the result of PRL on every 3 month follow-up visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on tumor volume measured by enhanced pituitary Magnetic Resonance Imaging（MRI）</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Record the tumor volume from enhanced pituitary MRI on every 3 month follow-up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of visual field scale</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Record the Visual field scale on every 3 month follow-up visit, 0 = normal, no vision loss; 1 = one quadrant vision loss; 2 = two quadrants of vision loss; 3 = three quadrants of vision loss; 4 = four quadrants of vision loss but retain a central tubular vision; 5 = blind</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of visual acuity</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Record the Visual acuity on every 3 month follow-up visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prolactinoma</condition>
  <arm_group>
    <arm_group_label>Drug treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume,visual acuity and visual field scale will be measured every 3 months.MRI showed that the tumors shrunk significantly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The CAB or BC fail to decrease prolactinoma size.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>The medication will be stopped if failure to decrease prolactinoma size and the subjects will be advised to endoscopic transphenoidal pituitary surgery .</description>
    <arm_group_label>Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug treatment</intervention_name>
    <description>The medication will continue if DA causes tumors to shrink.</description>
    <arm_group_label>Drug treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hyperprolactinemia;

          2. Enhanced pituitary MRI shows sella regional tumor;

          3. Aged between 18 and 65 years old, either sex;

          4. Karnofsky performance status ≥ 70;

          5. The patient has signed the informed consent.

        Exclusion Criteria:

          1. Patients concomitantly taking the psychotropic drugs or other drugs causing elevated
             PRL ;

          2. Patients with parkinson disease and is taking dopaminergic agents;

          3. Patients with prolactinoma who received Gamma knife treatment;

          4. Pregnant or lactating women, or women preparing pregnant;

          5. Patients with poor compliance, who cannot implement the program strictly.

          6. History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to cabergoline.

          7. Patients with claustrophobia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weiting Gu, MD</last_name>
    <phone>0086-13917778956</phone>
    <email>nowaiting1221@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhebao Wu, Medical PhD</last_name>
    <phone>0086-021-64370045</phone>
    <email>zhebaowu@aliyun.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Mukherjee J, Majji D, Kaur J, Constantinescu CC, Narayanan TK, Shi B, Nour MT, Pan ML. PET radiotracer development for imaging high-affinity state of dopamine D2 and D3 receptors: Binding studies of fluorine-18 labeled aminotetralins in rodents. Synapse. 2017 Mar;71(3). doi: 10.1002/syn.21950. Epub 2016 Nov 30.</citation>
    <PMID>27864853</PMID>
  </results_reference>
  <results_reference>
    <citation>Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273-88. doi: 10.1210/jc.2010-1692. Review.</citation>
    <PMID>21296991</PMID>
  </results_reference>
  <results_reference>
    <citation>Schönitzer V, Haasters F, Käsbauer S, Ulrich V, Mille E, Gildehaus FJ, Carlsen J, Pape M, Beck R, Delker A, Böning G, Mutschler W, Böcker W, Schieker M, Bartenstein P. In vivo mesenchymal stem cell tracking with PET using the dopamine type 2 receptor and 18F-fallypride. J Nucl Med. 2014 Aug;55(8):1342-7. doi: 10.2967/jnumed.113.134775. Epub 2014 Jul 14.</citation>
    <PMID>25024426</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 14, 2018</study_first_submitted>
  <study_first_submitted_qc>October 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>November 19, 2018</last_update_submitted>
  <last_update_submitted_qc>November 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Zhebao Wu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Dopamine agonist</keyword>
  <keyword>Dopamine D2 receptors</keyword>
  <keyword>PET-MR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolactinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The individual patient Data would not be shared to the third facility, but the sponsor hasn't decided whether to share the individual patient date to the other related studies hold by himself in the future.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

